Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis France
Original Assignee
Roussel Uclaf SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from FR934107Aexternal-prioritypatent/FR1453210A/fr
Application filed by Roussel Uclaf SAfiledCriticalRoussel Uclaf SA
Priority to FR943462ApriorityCriticalpatent/FR3031M/fr
Application grantedgrantedCritical
Publication of FR3031MpublicationCriticalpatent/FR3031M/fr
C07J41/00—Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
C—CHEMISTRY; METALLURGY
C07—ORGANIC CHEMISTRY
C07J—STEROIDS
C07J75/00—Processes for the preparation of steroids in general
FR943462A1963-05-081963-08-01Nouveau médicament notamment pour le traitement de l'hypercholestérolémie et des troubles en résultant.
ExpiredFR3031M
(fr)
Nouveau médicament, notamment pour le traitement des troubles de l'anabolisme protidique, des manifestations de l'hypoandrogénie et de l'hyperfolliculine.